View in EDS HTML Full Text PDF Full Text

Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis.

Saved in:
Bibliographic Details
Title: Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis.
Authors: Hall, V. G.1,2 (AUTHOR), Lim, C.3 (AUTHOR), Saunders, N. R.3 (AUTHOR), Klimevski, E.3 (AUTHOR), Nguyen, T. H. O.4 (AUTHOR), Kedzierski, L.4 (AUTHOR), Seymour, J. F.1,2 (AUTHOR), Wadhwa, V.5 (AUTHOR), Thursky, K. A.1,3 (AUTHOR), Yong, M. K.1,3 (AUTHOR), Kedzierska, K.4 (AUTHOR), Slavin, M. A.1,3 (AUTHOR), Teh, B. W.1,3 (AUTHOR)
Source: Leukemia & Lymphoma. Sep2023, Vol. 64 Issue 9, p1600-1604. 5p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2023.2224472